Forest Laboratories (NYSE:FRX) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a report issued on Friday. They currently have a $99.00 price objective on the stock. Forest Laboratories, Inc. (NYSE:FRX) net profit margin is 4.50% and weekly performance is -0.57%. On last trading day company shares ended up $94.24. Analysts mean target price for the company is $91.00. Forest Laboratories, Inc. (NYSE:FRX) distance from 50-day simple moving average is 2.53%.
On May 29, 2014 Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced the appointment of Paul Eng, Ph.D., as Senior Vice President, Drug Development. Dr. Eng will lead all clinical development operations for Synergy’s pivotal phase 3 program with plecanatide in patients with irritable bowel syndrome with constipation (IBS-C). Synergy Pharmaceuticals Inc (NASDAQ:SGYP) shares advanced 0.24% in last trading session and ended the day on $4.23. SGYP its return on assets is -71.60%. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) quarterly performance is -30.54%.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will present a corporate update at the Goldman Sachs 35th Annual Global Healthcare Conference on Wednesday, June 11, 2014 at 2:00 p.m. Pacific Time/5:00 p.m. Eastern Time at the Terranea Resort in Rancho Palos Verdes, Calif. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares moved up 1.90% in last trading session and was closed at $14.50, while trading in range of $14.07-$14.59. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) year to date performance is 24.89%.
Pernix Therapeutics Holdings (NYSE:PTX) was upgraded by analysts at Aegis to a “buy” rating in a research report issued to clients and investors on Tuesday.Pernix Therapeutics Holdings Inc (NASDAQ:PTX) ended the last trading day at $6.86. Company weekly volatility is calculated as 4.38% and price to cash ratio as 4.64. Pernix Therapeutics Holdings Inc (NASDAQ:PTX) showed a negative weekly performance of -3.52%.
Theravance Inc (NASDAQ:THRX) announced the completion of the separation of Theravance Biopharma, Inc., the research and development-based biopharmaceutical business, from Theravance, Inc. to form two, independent, publicly traded companies with differing business objectives and opportunities, via a dividend distribution of Theravance Biopharma shares to Theravance stockholders. Theravance Inc (NASDAQ:THRX) weekly performance is 7.36%. On last trading day company shares ended up $24.79. Analysts mean target price for the company is $36.57. Theravance Inc (NASDAQ:THRX) distance from 50-day simple moving average is 9.38%.
Leave a Reply